Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Activated B Cell Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TOPK (1) Akt (2) Apoptosis (7) Bacterial (4) Btk (4) c-Myc (1) Calmodulin (1) Cathepsin (1) CDK (1) COX (2) E1/E2/E3 Enzyme (3) EGFR (1) ERK (1) Fatty Acid Synthase (FASN) (3) Histone Acetyltransferase (1) Histone Methyltransferase (1) HSP (1) HSV (1) IFNAR (1) Interleukin Related (1) LPL Receptor (1) MALT1 (2) MAP4K (2) Mitochondrial Metabolism (1) Monoamine Oxidase (1) Necroptosis (1) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) p38 MAPK (2) Parasite (2) Phosphatase (3) PPAR (1) PROTACs (1) PTEN (2) Pyroptosis (1) ROCK (1) SHP2 (2) Sirtuin (2) STAT (2) TNF Receptor (5) TrxR (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (20) Metabolic Disease (6) Neurological Disease (2)

By Targets:

TOPK (1)

Akt (2)

Apoptosis (7)

Bacterial (4)

Btk (4)

c-Myc (1)

Calmodulin (1)

Cathepsin (1)

CDK (1)

COX (2)

E1/E2/E3 Enzyme (3)

EGFR (1)

ERK (1)

Fatty Acid Synthase (FASN) (3)

Histone Acetyltransferase (1)

Histone Methyltransferase (1)

HSP (1)

HSV (1)

IFNAR (1)

Interleukin Related (1)

LPL Receptor (1)

MALT1 (2)

MAP4K (2)

Mitochondrial Metabolism (1)

Monoamine Oxidase (1)

Necroptosis (1)

NF-κB (1)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

p38 MAPK (2)

Parasite (2)

Phosphatase (3)

PPAR (1)

PROTACs (1)

PTEN (2)

Pyroptosis (1)

ROCK (1)

SHP2 (2)

Sirtuin (2)

STAT (2)

TNF Receptor (5)

TrxR (1)

By Research Areas:

Cancer (30)

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (20)

Metabolic Disease (6)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-129390

Orelabrutinib ICP-022	Btk	Cancer
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .

HY-141432

NX-1607 Cbl-b-IN-3	E1/E2/E3 Enzyme	Cancer
Cbl-b-IN-3 (Compound 23) is a casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) inhibitor with an IC₅₀ of < 1 nM. Cbl-b is an E3 ubiquitin ligase that negatively regulates T-cell activation .

HY-105118A

Zaldaride maleate CGS-9343B; KW 5617	Calmodulin	Neurological Disease Metabolic Disease Inflammation/Immunology
Zaldaride maleate (CGS-9343B) is a potent, orally active and selective inhibitor of calmodulin. Zaldaride maleate (CGS-9343B) inhibits CaM (calmodulin)-stimulated cAMP phosphodiesterase activity, with an IC₅₀ of 3.3 nM . Zaldaride maleate (CGS-9343B) prevents estrogen-induced transcription activation by ER, reversibly blocks voltage-activated Na ⁺, Ca ²⁺ and K ⁺ currents in PC12 cells and inhibits nAChR .

HY-155477

Cbl-b-IN-15	E1/E2/E3 Enzyme	Cancer
Cbl-b-IN-15 (compound 25) is an inhibitor of the RING finger E3 ligase Cbl (IC₅₀: 15 nM). *Cbl-b* refers to Casitas B-lineage lymphoma proto-oncogene-b, which inhibits T-cell, natural killer (NK) cell, and B-cell activation. Cbl-b-IN-15 activates T cell function with EC₅₀=0.41 μM .

HY-156769

Cbl-b-IN-13

E1/E2/E3 Enzyme Inflammation/Immunology

Cbl-b-IN-13 (Example 520) is a Cbl-b inhibitor with an IC₅₀ of <100 nM. Cbl-b-IN-13 has the ability to activate T-cells .

Cbl-b-IN-13	E1/E2/E3 Enzyme	Inflammation/Immunology
Cbl-b-IN-13 (Example 520) is a *Cbl-b* inhibitor with an IC₅₀ of <100 nM. Cbl-b-IN-13 has the ability to activate T-cells .

HY-160698

SGR-1505	MALT1	Cancer
SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas .

HY-128403

BTK inhibitor 8	Btk	Inflammation/Immunology
BTK inhibitor 8 (Compound 27) is a Btk inhibitor with an IC₅₀ of 0.11 nM. BTK inhibitor 8 inhibits B cell activation in hWB with an IC₅₀ of 2 nM .

HY-P9952

Belimumab 2 Publications Verification LymphoStat B	TNF Receptor	Inflammation/Immunology
Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits *B-cell* activating factor (BAFF)**. Belimumab can be used for systemic lupus erythematosus (SLE) research .

HY-N4171

Dihydrocucurbitacin B	Apoptosis	Inflammation/Immunology
Dihydrocucurbitacin B, a triterpene isolated from Cayaponia tayuya roots, inhibits nuclear factor of activated T cells (NFAT), induces cell cycle arrested in the G0 phase, and inhibits delayed type hypersensitivity .

HY-130369

NSC10010 hydrochloride	Bacterial Necroptosis HSV	Infection Cancer
NSC10010 hydrochloride inhibits gammaherpesvirus associated B-lymphomas growth through activation of NF-kB and c-Myc-mediated signaling pathways. NSC10010 hydrochloride induces necrotic cell death in gammaherpesvirus infected B-cells. NSC10010 hydrochloride is also an inhibitor of Mtb ClpC1 ATPase .

HY-111053

P11	Others	Cancer
P11 is a selective inhibitor of platelet-activating factor acetylhydrolases (PAFAHs) 1b2 and 1b3 that impairs cancer cell survival. P11 exhibits IC₅₀ values of ~40 and 900 nM for PAFAH1b2 and 1b3, respectively .

HY-P99482

Blisibimod A 623; AMG 623	TNF Receptor	Inflammation/Immunology
Blisibimod (A 623) is a potent and selective tetravalent inhibitor of *B-cell* activating factor (BAFF)**. Blisibimod can be used for the research of systemic lupus erythematosus (SLE) .

HY-101287

MPT0B392
MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line .

HY-14452

Fatostatin Maximum Cited Publications 19 Publications Verification 125B11	Fatty Acid Synthase (FASN)	Cancer
Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice .

HY-120231

Z-VRPR-FMK	MALT1	Cancer
Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .

HY-N10009

Cudraflavone B	NF-κB TNF Receptor COX ERK p38 MAPK Sirtuin	Inflammation/Immunology
Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of COX-1 and COX-2. Cudraflavone B blocks the translocation of nuclear factor κB (NF-κB) from the cytoplasm to the nucleus in macrophages. Thus, Cudraflavone B inhibits tumor necrosis factor α (TNFα) gene expression and secretion. Cudraflavone B also triggers the mitochondrial apoptotic pathway, activates NF-κB, the MAPK p38, and ERK, and induced the expression of SIRT1. Thus Cudraflavone B inhibits the growth of human oral squamous cell carcinoma cells .

HY-14452A

Fatostatin hydrobromide Maximum Cited Publications 19 Publications Verification 125B11 hydrobromide	Fatty Acid Synthase (FASN)	Cancer
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice .

HY-161351

STAT3/AKT-IN-1	Akt STAT Apoptosis	Cancer
STAT3/AKT-IN-1 is a dual inhibitor for the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signalling pathway, exhibits antitumor activity against gastric cancer and induces cell apoptosis in SGC-7901 cells .

HY-N8371

Shizukaol B	NO Synthase COX Interleukin Related TNF Receptor	Inflammation/Immunology
Shizukaol B is a lindenane-type dimeric sesquiterpene, used to be isolated from the whole plant of Chloranthus henryi. Shizukaol B has anti-inflammatory effect against lipopolysaccharide (LPS)-induced activation of BV2 microglial cells. Shizukaol B inhibits iNOS and COX-2, and suppresses NO production, TNF-α, and IL-1β expression .

HY-155577

MAO A/HSP90-IN-1	Monoamine Oxidase HSP	Cancer
MAO A/HSP90-IN-1 (4-b) is a MAO A/HSP90 dual inhibitor with IC₅₀ value of 1.77 μM and 0.019 μM in Glioblastoma (GBM) GL26 cells and HSP90α, respectively. MAO A/HSP90-IN-1 (4-b) can inhibit MAO A activity, HSP90 binding and the expression of HER2 and phospho-Akt to inhibit the growth of GBM, they also reduce PD-L1 expression, which inhibits T cell activation. MAO A/HSP90-IN-1 (4-b) have potential to inhibit tumor immune escape. MAO A/HSP90-IN-1 (4-b) can be used for brain tumor-related diseases research .

HY-12467

OTS964 hydrochloride 5+ Cited Publications	TOPK CDK Apoptosis	Cancer
OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC₅₀ of 28 nM . OTS964 hydrochloride is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a K_d of 40 nM .

HY-136093B

Lixumistat IM156 free base; HL156A free base; HL271 free base	Mitochondrial Metabolism	Cancer
Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus .

HY-142932

BTK-IN-6	Btk	Neurological Disease Inflammation/Immunology Cancer
BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8) .

HY-145686

AV023	Others	Inflammation/Immunology
AV023 is a potent inhibitor of ANKRD22. AV023 promotes the expansion of gastrointestinal mucosal epithelial stem cells and indirectly activates the Wnt classical pathway, which helps the recovery of damaged gastrointestinal mucosal tissues in the body (extracted from patent CN111205231B) .

HY-114374

RO5461111	Cathepsin	Inflammation/Immunology
RO5461111 a highly specific and orally active antagonist of Cathepsin S with IC₅₀s of 0.4 nM (human Cathepsin S) and 0.5 nM (murine Cathepsin S), respectively. RO5461111 can effectively inhibit the activation of antigen-specific T cells and B cells. RO5461111 can improve pulmonary inflammation and lupus nephritis .

HY-154860

PTD10	PROTACs Btk	Cancer
PTD10 is a highly potent PROTAC BTK degrader (DC₅₀: 0.5 nM, K_D: 2.28 nM). PTD10 degrades BTK in Ramos and JeKo-1 cells with DC₅₀s of 0.5 and 0.6 nM respectively. PTD10 inhibits cell growth, and induces cell apoptosis via activation of the caspase-dependent pathway and mitochondrial pathway. PTD10 can be used for research of B-cell dysregulation .

HY-155864

AJ2-30	Others	Inflammation/Immunology
AJ2-30 is a SLCl5A4 inhibitor. AJ2-30 inhibits TLR9-mediated B cell activation. AJ2-30 block endogenous NOD signaling in human and mouse macrophages. AJ2-30 can be used for research of inflammation .

HY-156154

Caspase-3 activator 1	Pyroptosis	Cancer
Caspase-3 activator 1 (compound 4b) is a Ru(III) metal complex that inhibits gastric tumor growth and metastasis. Caspase-3 activator 1 mediates caspase-3 cleavage, which in turn causes Caspase-3 to cleave gasdermin E (GSDME) to produce the GSDME-N terminus, causing gastric tumor cell membrane perforation. Caspase-3 activator 1 is capable of inducing pyroptosis and pyroptosis-induced immune responses and can be assembled with decitabine DCT (HY-A0004) into a 4b-DCT-Lip lipid delivery system .

HY-N0704

Agrimol B	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial	Infection Metabolic Disease Cancer
Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27 .

HY-139061

Palmitoyl 3-carbacyclic phosphatidic acid	LPL Receptor ROCK	Cancer
Palmitoyl 3-carbacyclic phosphatidic acid (HY-139061) is a palmitoylated Carba-like cyclophosphatidic acid and an analog of lysophosphatidic acid (LPA). Palmitoyl 3-carbacyclic phosphatidic acid has different functions from LPA and can inhibit the activation of RhoA and inhibit the migration of melanoma cells. Palmitoyl 3-carbacyclic phosphatidic acid effectively inhibited experimental lung metastasis and reduced the number of tumor nodules in a B16-F0 xenograft mouse model .

HY-122872

MKK7-COV-9	p38 MAPK	Cancer
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC₅₀ of 4.98 μM .

HY-18935

CBL0137 Curaxin 137; CBL-C137
CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates *NF-?B* and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis .

HY-143869

HPK1-IN-28	MAP4K	Cancer
HPK1-IN-28 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1) .

HY-143870

HPK1-IN-29	MAP4K	Cancer
HPK1-IN-29 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38) .

HY-P3444

CD31 PECAM-1	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of SHP2 and to inhibit TCR-induced T-cell activation ^- .

HY-146350

TrxR-IN-4	TrxR	Cancer
TrxR-IN-4 (Compound 1b) is a potent inhibitor of TrxR. TrxR-IN-4 induces HepG2 cells apoptosis by activating the endoplasmic reticulum stress (ERS). TrxR-IN-4 improves the CCl4-induced liver damage in vivo by down-regulation of TrxR expression and inflammation level .

HY-P3444A

CD31 TFA PECAM-1 TFA	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of SHP2 and to inhibit TCR-induced T-cell activation ^- .

HY-150749

ODN D-SL03	IFNAR	Inflammation/Immunology Cancer
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-100671

L002	Histone Acetyltransferase STAT	Inflammation/Immunology Cancer
L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC₅₀ of 1.98 μM . L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation . L002 has the potential for hypertension‐induced cardiac hypertrophy and fibrogenesis treatment .

HY-108543

NSC 95397 4 Publications Verification	Phosphatase Apoptosis	Cancer
NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (K_i=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC₅₀=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)) . NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway .

HY-136065

bpV(phen)	PTEN Phosphatase Parasite Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
bpV(phen), a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and *PTP-1B, respectively. bpV(phen) inhibits* proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .

HY-120323

DRI-C21045 1 Publications Verification	TNF Receptor	Inflammation/Immunology
DRI-C21045 (compound 10) is a potent and selective inhibitor of the CD40-CD40L costimulatory protein-protein interaction (PPI) with an IC₅₀ of 0.17 µM. DRI-C21045 shows concentration-dependent inhibition of the activation of NF-κB and B cell proliferation all induced by CD40L with IC₅₀s of 17.1 µM and 4.5 µM, respectively .

HY-131040

NLRP3-IN-NBC6	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC₅₀= 574 nM) that acts independently of Ca ²⁺. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .

HY-122818

bpV(phen) trihydrate 2 Publications Verification	PTEN Phosphatase Parasite Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
bpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and *PTP-1B, respectively. bpV(phen) trihydrate inhibits* proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .

HY-156152

CARM1 degrader-1	Histone Methyltransferase	Cancer
PROTAC CARM1 degrader-1 (compound 3b) is a degrader (DC₅₀=8.1 nM) of co-activator associated argininemethyltransferase (CARM1). PROTAC CARM1 degrader-1 degrades CARM1 in a VHL- and proteasome-dependent manner. Thus, PROTAC CARM1 degrader-1 inhibits methylation of CARM1 substrates such as poly(A)-binding protein PABP1 and BGR1-associated factor BAF155 and inhibits breast cancer cell migration .

HY-108052

Delphinidin 3-glucoside chloride Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride	EGFR Apoptosis Akt	Cardiovascular Disease Cancer
Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC₅₀ of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC₅₀ of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks